Clinical Trial Update: Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in individuals with elevated uric acid levels related to gout.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout

Drugs mentioned

• SEL-212

Snippet

Sponsor: Selecta Biosciences, Inc. | Conditions: Gout | Phase 1 | Status: COMPLETED